Literature DB >> 29552768

The expression and mechanism of Sirt1 and AMPK in nonsmall cell lung cancer.

Fushen Yang1.   

Abstract

PURPOSE: To investigate the expression of sirtuin type 1 (Sirt1) and adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) in non-small cell lung cancer (NSCLC), and to explore the mechanism of their functions in NSCLC.
METHODS: Cancer tissues (NSCLC group) and the adjacent normal healthy tissues (control group) of 50 patients with NSCLC were selected, and H&E staining was performed to identify the histopathological differences. Reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence staining and Western blot were performed to detect the expression of Sirt1 and AMPK in tissues of NSCLC group and control group. SPSS17.0 statistical software was used to analyze the differences in the expression of Sirt1 and AMPK between control group and NSCLC group.
RESULTS: Significant differences in histopathological structure were found between NSCLC and control group by H&amp;E staining. Compared with control group, cell structure in NSCLC group was destroyed and condensed nuclei were observed, indicating the lung injury. Results of RT-PCR, immunofluorescence staining and Western blot showed that the expression levels of Sirt1 and AMPK were significantly lower in the NSCLC group than in the control group at both mRNA and protein levels. Results of variance analysis showed significant differences in the expression levels of Sirt1 and AMPK between control group and NSCLC group (p<0.01).
CONCLUSION: The abnormal expression of Sirt1 and AMPK was closely related to the occurrence and development of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29552768

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  1 in total

1.  Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells.

Authors:  Wonchung Lim; Chounghun Kang
Journal:  Anim Cells Syst (Seoul)       Date:  2020-04-02       Impact factor: 1.815

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.